Literature DB >> 21111556

Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma.

Stefan H Hohnloser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111556     DOI: 10.1016/j.jacc.2010.09.026

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  4 in total

Review 1.  Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.

Authors:  Christopher J Varughese; Jonathan L Halperin
Journal:  J Interv Card Electrophysiol       Date:  2012-05-22       Impact factor: 1.900

2.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

Authors:  Shaun G Goodman; Daniel M Wojdyla; Jonathan P Piccini; Harvey D White; John F Paolini; Christopher C Nessel; Scott D Berkowitz; Kenneth W Mahaffey; Manesh R Patel; Matthew W Sherwood; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Gunter Breithardt; Keith A A Fox; Robert M Califf
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

Review 3.  Anemia and iron deficiency in patients with atrial fibrillation.

Authors:  Nicole Hanna-Rivero; Samuel J Tu; Adrian D Elliott; Bradley M Pitman; Celine Gallagher; Dennis H Lau; Prashanthan Sanders; Christopher X Wong
Journal:  BMC Cardiovasc Disord       Date:  2022-05-04       Impact factor: 2.174

Review 4.  Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis.

Authors:  Wenbin Fu; Hongyang Guo; Jianping Guo; Kun Lin; Haijun Wang; Yu Zhang; Yutang Wang; Zhaoliang Shan
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2014-12       Impact factor: 2.160

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.